INKT Key Statistics, Chart & Performance
The current stock price of INKT is 12.78 USD. In the past month the price increased by 7.39%. In the past year, price increased by 39.52%.
INKT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is one of the better performing stocks in the market, outperforming 76.78% of all stocks.
INKT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INKT Forecast & Estimates
8 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 211.27% is expected in the next year compared to the current price of 12.78.
INKT Ownership
About INKT
Company Profile
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Company Info
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK US
Employees: 23
Phone: 12129948250
MINK THERAPEUTICS INC / INKT FAQ
Can you describe the business of MINK THERAPEUTICS INC?
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
What is the stock price of MINK THERAPEUTICS INC today?
The current stock price of INKT is 12.78 USD. The price increased by 2.24% in the last trading session.
What is the dividend status of MINK THERAPEUTICS INC?
INKT does not pay a dividend.
What is the ChartMill rating of MINK THERAPEUTICS INC stock?
INKT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
When does MINK THERAPEUTICS INC (INKT) report earnings?
MINK THERAPEUTICS INC (INKT) will report earnings on 2026-03-16, after the market close.
Can you provide the ownership details for INKT stock?
You can find the ownership structure of MINK THERAPEUTICS INC (INKT) on the Ownership tab.